Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 5.9% - Time to Sell?

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) fell 5.9% during mid-day trading on Thursday . The stock traded as low as $20.44 and last traded at $20.60. 144,792 shares were traded during mid-day trading, a decline of 70% from the average session volume of 481,570 shares. The stock had previously closed at $21.89.

Analyst Upgrades and Downgrades

Several research firms have issued reports on ARCT. HC Wainwright reiterated a "buy" rating and issued a $63.00 target price on shares of Arcturus Therapeutics in a research note on Tuesday, October 1st. Leerink Partnrs upgraded shares of Arcturus Therapeutics to a "strong-buy" rating in a research report on Monday, August 12th. Cantor Fitzgerald reissued an "overweight" rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Finally, Leerink Partners began coverage on Arcturus Therapeutics in a research note on Monday, August 12th. They issued an "outperform" rating and a $70.00 price target on the stock. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $71.40.

Arcturus Therapeutics Stock Performance

The stock has a market capitalization of $555.07 million, a P/E ratio of -5.27 and a beta of 2.61. The stock has a 50-day moving average price of $20.95 and a two-hundred day moving average price of $25.93.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Monday, August 5th. The biotechnology company reported ($0.64) earnings per share for the quarter, beating the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The business had revenue of $49.86 million for the quarter, compared to analysts' expectations of $21.00 million. During the same quarter in the previous year, the business posted ($1.98) earnings per share. Equities analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. bought a new position in shares of Arcturus Therapeutics in the 1st quarter worth about $40,000. Quest Partners LLC increased its stake in shares of Arcturus Therapeutics by 3,283.5% during the second quarter. Quest Partners LLC now owns 3,688 shares of the biotechnology company's stock valued at $90,000 after purchasing an additional 3,579 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Arcturus Therapeutics during the second quarter valued at approximately $142,000. CANADA LIFE ASSURANCE Co boosted its position in shares of Arcturus Therapeutics by 10.5% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company's stock worth $152,000 after purchasing an additional 428 shares in the last quarter. Finally, Public Employees Retirement System of Ohio grew its stake in shares of Arcturus Therapeutics by 63.8% in the 1st quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company's stock worth $156,000 after buying an additional 1,800 shares during the last quarter. Hedge funds and other institutional investors own 94.54% of the company's stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.